LXRX Q1 2023 Earnings — Lexicon Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

LXRXLexicon Pharmaceuticals, Inc.

$704M

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$24,000-35.1% YoY

Gross Profit

$24,000100.0% margin

Operating Income

-$31M-129758.3% margin

Net Income

-$32M-133058.3% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-14.3%

Cash Flow

Operating Cash Flow

-$32M

Free Cash Flow

-$32M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$163M

Total Liabilities

$75M

Stockholders' Equity

$88M

Cash & Equivalents

$26M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$24,000	$37,000	-35.1%
Gross Profit	$24,000	-$72,000	+133.3%
Operating Income	-$31M	-$23M	-33.2%
Net Income	-$32M	-$23M	-36.0%